Treats migraine attacks with or without aura. ANDA 215891, held by Torrent. Diclofenac Potassium.
As of Nov 16, 2026, ANDA 215891 (Diclofenac Potassium), held by Torrent, was first approved by FDA on Jan 22, 2025, with 0 approved supplements and 0 published complete response letters.
Diclofenac potassium for oral solution is indicated for the acute treatment of migraine attacks with or without aura in adults (18 years of age or older). Limitations of Use: Diclofenac potassium for oral solution is not indicated for the prophylactic therapy of migraine. The safety and effectiveness of diclofenac potassium for oral solution have not been established for cluster headache, which is present in an older, predominantly male population.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jan 22, 2025 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Diclofenac Potassium50MG · for solution;oral | Diclofenac Potassium | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters